Draper and Dash HealthCare (t/a RwHealth) secures £6.2 million Series A led by Maven VC
Summary
The capital will help clinicians manage elective recovery backlogs in the NHS and advanced clinical research in areas such as acute myeloid leukaemia (AML), CAR-T and other diseases as the healthcare industry attempts to recover post-Covid. By using RwHealth’s deep analytical capability to make predictions, model treatment options, improve safety and increase efficiency, clinicians can deliver better care to more people. Orlando Agrippa, CEO and Founder of RwHealth, said: “As we continue to accelerate and invest in the ethical use of clinical research data to advance new medicines for patient care, this funding gives us the capital needed to carry out our immediate plans while delivering AI solutions which will help futureproof our NHS. “The raise will support our work with UK and US healthcare partners, helping us to provide deeper clinical care technologies, while supporting post-pandemic recovery efforts with our AI Data Science Platform.” “RwHealth is at the forefront of the drive to use real world evidence and predictive analytics more effectively in the healthcare and pharma sectors – ultimately, this will enable better patient outcomes and will be more vital than ever in the post pandemic era. Its successful platform has helped many of the UK’s hospitals to combat bed shortages and tackle waiting list issues which have worsened during and immediately after the pandemic.